Zacks Research Has Positive Outlook of UTHR FY2025 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Analysts at Zacks Research upped their FY2025 earnings estimates for United Therapeutics in a report issued on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $26.77 for the year, up from their prior estimate of $25.76. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics’ Q4 2025 earnings at $6.57 EPS, Q1 2026 earnings at $7.03 EPS, Q2 2026 earnings at $6.96 EPS, Q4 2026 earnings at $6.27 EPS, FY2026 earnings at $27.65 EPS, Q1 2027 earnings at $6.96 EPS and Q2 2027 earnings at $6.73 EPS.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.39 EPS.

A number of other equities research analysts have also recently issued reports on UTHR. Wells Fargo & Company boosted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a report on Wednesday. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Trading Down 0.4%

United Therapeutics stock opened at $474.72 on Friday. The business’s 50 day simple moving average is $438.38 and its 200 day simple moving average is $354.25. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $485.32. The company has a market cap of $20.44 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 4.96 and a beta of 0.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the second quarter valued at $29,000. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at about $32,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 515,935 shares of company stock worth $222,980,817 over the last ninety days. 10.30% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.